🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Poland / NCT07519720
Active, not recruiting Observational

An Assessment of Risk Factors for Osteosarcopenia in Older Adults - the Role of Prevention, Lifestyle, Physical Activity and Education.

NCT07519720 · tracked via the Priya Life Science Poland tracker
Phase
Observational
Started
2025-09-09
Last updated
2026-04-13

Condition(s) studied

Osteosarcopenia

Investigational drug(s) / intervention(s)

As part of the study, participants will undergo body composition analysis, bone density testing, and tests of physical fitness and handgrip strength in both the older and younger age groups.

As part of the study, participants will undergo body composition analysis, bone density testing, and tests of physical fitness and handgrip strength in both the older and younger age groups.: The study will examine the relationship between the frequency of falls and fractures and the parameters obtained in the studies regarding body composition, muscle strength and functional fitness, as well as age, gender, lifestyle, current levels of physical activity and dietary habits.

Study summary

The aim of the study is to assess the risk factors for osteosarcopenia in older adults, taking into account physical activity, healthy eating habits and education.

During the project, the following will be assessed: bone density, handgrip strength, physical activity, functional physical fitness, the incidence of falls and bone fractures over the last 10 years, and dietary habits. The results of the study will then be compared with those of a younger population.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * people aged 60-80, * people who are independent and have no mobility limitations requiring the use of assistive devices (wheelchair, walking frame), * people who are mentally alert and show no signs of dementia, * people with no current acute medical conditions, * people who have given their informed consent to participate in the study. Exclusion Criteria: * musculoskeletal injuries that have limited physical ability in the last 3 months, * a recent bone densitometry scan using dual-energy X-ray absorptiometry (DXA), carried out within the last 12 months, * chronic conditions in an acute phase (e.g. rheumatoid arthritis, advanced-stage diabetes), * inability to cooperate, e.g. due to language or cognitive barriers.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Wroclaw University of Health and Sport Sciences, Poland Wroclaw Poland

More Wroclaw University of Health and Sport Sciences trials in Poland

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07519720 on ClinicalTrials.gov ↗ ← All trials in Poland